Addex Pharmaceuticals (SWISS: ADXN) announced that it has decided to end prematurely the migraine prevention study 206. Routine safety monitoring of blinded data in study 206 has revealed an incidence of abnormalities of liver function tests that is higher than expected in this population. The abnormalities are apparent from day 28 of dosing but the incidence and severity appear to increase progressively with increasing duration of participation in the study...
More...
More...